Physician profile
Roberta Beals
NPI 1013988211
$2,419.65
in general payments reported to CMS, 2019-2025
28 companies · $597 in 2025
The $597 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $139 · 2021: $315 · 2022: $354 · 2023: $168 · 2024: $610 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,374.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $471.63 | 2021-2025 | Vraylar |
| Pfizer INC. | $320.62 | 2021-2025 | |
| Novo Nordisk INC | $296.92 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $201.17 | 2024-2025 | Veozah |
| Lilly USA, LLC | $179.29 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $167.74 | 2021-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $111.76 | 2022-2025 | Trelegy Ellipta, Shingrix, Boostrix |
| Amgen INC. | $95.83 | 2022-2025 | Evenity |
| Boston Scientific Corporation | $52.25 | 2022-2025 | General - Therapies, Watchman |
| Novartis Pharmaceuticals Corporation | $47.35 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $44.48 | 2024-2025 | Spravato |
| Dexcom, INC. | $44.29 | 2022-2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $43.03 | 2020-2025 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $35.59 | 2021-2023 | |
| Edwards Lifesciences Corporation | $29.86 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $29.60 | 2024 | Rexulti |
| Irhythm Technologies, INC. | $29.51 | 2023 | Zio Xt Patch |
| Biosense Webster, INC. | $26.11 | 2025 | Carto 3 |
| Radius Health, INC. | $24.93 | 2025 | Tymlos |
| Corium, LLC | $24.49 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.02 | 2025 | Gvoke Hypopen |
| Supernus Pharmaceuticals, INC. | $20.19 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.77 | 2025 | Xifaxan |
| Dova Pharmaceuticals | $18.81 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.51 | 2021 | |
| Allergan, INC. | $15.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.86 | 2020 | |
| Kyowa Kirin, INC. | $14.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Beals listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.